The Expanding Reach of Obesity Drugs, Reshaping Industries and Society Beyond the Dinner Table

GLP-1-Driven Shift in Food Consumption Patterns
Global Food Companies Race to Develop Nutrition-Focused Products
Economic Impact Extending to Productivity and GDP

Glucagon-like peptide-1 (GLP-1) obesity drugs, which suppress appetite, are reshaping consumer markets. Global food companies are rolling out products tailored to users of these medications, while consumers are increasingly prioritizing nutritional value over calorie counts when selecting food. Market observers believe these changes will extend beyond the restructuring of the food industry, ultimately influencing productivity and broader economic growth.

GLP-1 Reshapes Eating Habits and Food Consumption Patterns

According to market research firm Euromonitor on July 2 (local time), the number of packaged food products sold through global online markets carrying labels such as "GLP-1 Friendly," indicating they may support GLP-1-related dietary needs, increased by approximately 37% in 2024 compared with the previous year. The increase reflects expanding product portfolios specifically targeting consumers using obesity medications.

Among the most prominent examples, U.S. food company Conagra Brands began attaching "GLP-1 Friendly" labels to 26 frozen food products early last year. Nestlé launched its frozen meal brand "Vital Pursuit" exclusively for GLP-1 users in 2024. Smoothie King now offers a dedicated "GLP-1 Support Menu," while meal-kit brand Factor introduced its "GLP-1 Balance" menu to capture rising demand. These products are distinguished by significantly higher protein and dietary fiber content, addressing common challenges faced by obesity drug users, including rapid weight loss that can make maintaining muscle mass difficult, as well as side effects such as constipation.

Other companies are also strengthening their protein-focused product portfolios in response to the trend. Coca-Cola announced in March that it would expand production capacity for its high-protein milk brand Fairlife this year following a surge in demand. PepsiCo CEO Ramon Laguarta highlighted the GLP-1 trend during the company's February earnings call, saying the company plans to expand smaller portion sizes while developing products enriched with protein and dietary fiber. General Mills likewise stated during last year's earnings announcement that "GLP-1 users are seeking more protein." The company subsequently launched its protein-enhanced cereal, Cheerios Protein, in late 2024.

A New Engine Transforming Household Spending and Productivity

The food industry's strategic shift reflects expectations that overall food consumption will decline significantly as the number of obesity drug users continues to rise. According to Bloomberg, Eli Lilly's Mounjaro became the world's top-selling pharmaceutical product last year, generating annual revenue of $35.9 billion. Denmark's Novo Nordisk followed closely with Wegovy, recording $35.6 billion in annual sales.

The impact of obesity drugs is already becoming evident in economic data. According to global consulting firm KPMG, households taking GLP-1 medications consumed an average of 21% fewer calories than before, while grocery spending fell by as much as 31%. Euromonitor characterized this shift as the beginning of the "Peak Calorie" era, in which humanity's calorie consumption has reached its high point and begun to decline. Consulting firm EY-Parthenon also projected that obesity drugs could reduce revenue for snack manufacturers and similar businesses by as much as $12 billion over the next decade. Numerous other industries are also expected to feel the effects. Analysts suggest airlines could benefit from lower fuel consumption as obesity rates decline, while demand for fitness centers and personal trainers may increase.

The influence of obesity medications is also spreading across the broader macroeconomy. Economists increasingly argue that wider adoption of GLP-1 drugs could reduce obesity and chronic diseases, improve labor productivity, ease healthcare spending, and ultimately support national economic growth. Some have even suggested that obesity drugs could lift U.S. gross domestic product (GDP) growth. Goldman Sachs Chief Economist Jan Hatzius projected that if 60 million people are taking obesity medications by 2028, U.S. GDP could increase by 1%. The logic is that a healthier workforce would boost productivity, reduce healthcare costs, and generate trillions of dollars in economic value.

Hatzius' analysis becomes even more compelling when viewed against the economic losses currently caused by obesity-related illness. He estimated that "if declining health did not constrain labor supply through lost working hours, illness and disability, premature mortality, and reduced labor force participation due to informal caregiving, GDP would be more than 10% higher than it is today." In other words, obesity and chronic diseases have long functioned as a massive drag on economic growth. Studies also show that obesity-related health complications reduce individual productivity by more than 3%. When combined with an adult obesity rate exceeding 40% in the United States, obesity alone is estimated to reduce total national economic output by more than 1%.

A Two-Tiered Obesity Drug Market

However, these changing consumption patterns are likely to emerge first among specific consumer groups. GLP-1 obesity medications such as Wegovy and Mounjaro remain expensive, while insurance coverage is still limited. As a result, affluent consumers have been the first to adopt these treatments, prompting food companies to adjust their product strategies to match evolving dietary preferences within this demographic.

Whereas the industry's traditional objective was to sell as much as possible to the broadest possible consumer base, the market is now increasingly shifting toward premium nutritional products and customized meal plans designed for consumers with greater purchasing power. The rapid rollout of dedicated product lines for GLP-1 users and the emphasis on protein- and fiber-enriched offerings reflect these evolving consumption trends.

More recently, analysts have suggested that access to obesity medications could itself become a new determinant of healthcare competitiveness. In the United States, concerns are growing that disparities in financial resources may translate into unequal access to obesity treatments, creating broader gaps in health outcomes. In particular, as the use of obesity medications among adolescents increases, household income may increasingly influence children's long-term health trajectories.

Experts, however, believe these changes will not remain confined to the premium segment. While adoption has initially been concentrated among higher-income consumers due to high drug prices, nutrition-focused consumption patterns are expected to spread rapidly throughout the broader food market as obesity drugs become more widely available and affordability improves. Earlier this year, oral Wegovy tablets received approval from the U.S. Food and Drug Administration (FDA) and entered the market. Eli Lilly's oral obesity drug orforglipron is also awaiting FDA approval. These oral treatments are reportedly priced at up to 40% less than injectable alternatives.